| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Femasys Inc. Common Stock$4
-0.19 (-4.53%)
F 2Pipeline Score MedTech · Clinical
Market Cap
23.98 M
EPS
-0.56
P/E Ratio
-0.71 $
Value Trade
259.33 K
SEC Financials
Q1 2026Dilution Risk
Revenue
424.89 K
R&D Expenses
1.31 M
Operating CF
-4.14 M
Total Assets
16.50 M
Total Liabilities
9.21 M
Equity
7.29 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
5.39 M
Monthly Burn
1.38 M
Runway
2.6 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
17.66 K
52 Week Range
0.31 - 1.29
% held by Insiders
8.96 %
% held by Institutions
15.71 %
Enterprise Value
19.41 M
Total Shares
58.50 M
Short %
6.05 %
Float Shares
35.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 870 of 905)
Percentile RankFemasys Inc. Common Stock has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FEMY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Femasys Inc. Common Stock (FEMY) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
FEMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FEMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FEMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FEMY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
FEMY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-FEMY
May 13, 2026Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys Inc. has received CE Mark approval for its FemHSG Catheter, enhancing its fertility care portfolio in Europe. This catheter, designed for in-office fertility evaluations, works in conjunction with the FemVue device. The approval aims to improve access to timely and affordable fertility diagnosis and treatment for women. CEO Kathy Lee-Sepsick emphasized the importance of expanding in-office fertility services.
Read more →-FEMY
May 5, 2026Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Femasys Inc. has launched FemaSeed as a first-line fertility treatment in OB/GYN practices, enabling in-office sperm preparation with FemSperm. This innovation addresses the significant gap in infertility care access, allowing earlier intervention at a lower cost. The approach aims to streamline fertility treatment, improving patient outcomes and satisfaction.
Read more →-FEMY
Apr 16, 2026Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
Femasys Inc. has entered a strategic partnership with AMI Technologies to introduce its fertility portfolio in Israel. This collaboration aims to enhance market access for innovative treatments like FemaSeed and FemVue, leveraging AMI's established infrastructure and expertise. The partnership is part of Femasys's broader strategy to expand its global footprint in women's health.
Read more →-FEMY
Apr 1, 2026Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Femasys Inc. reported its financial results for the year ending December 31, 2025, highlighting significant clinical and regulatory advancements. The company is actively enrolling patients in the FINALE pivotal trial for its FemBloc product, aiming for FDA approval. Additionally, Femasys is expanding its FemaSeed commercialization efforts in the U.S. market.
Read more →-FEMY
Mar 2, 2026Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 27, 2026
Femasys Inc. has announced the granting of stock options to two new non-executive employees as part of their inducement grants under Nasdaq Listing Rule 5635(c)(4). The options, totaling 185,000 shares, were granted at prices reflecting the stock's closing value. This move aims to attract talent while ensuring compliance with regulatory standards.
Read more →-FEMY
Feb 26, 2026Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
Femasys Inc. announced that its FemBloc permanent birth control system has received MDSAP certification, facilitating regulatory and commercial execution in key global markets. This certification enhances the company's manufacturing credibility and operational scalability, supporting ongoing commercialization efforts. FemBloc is positioned as a non-surgical alternative to traditional sterilization, aiming to expand access to permanent contraception.
Read more →-FEMY
Feb 23, 2026Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
Femasys Inc. has received approval from the AMA for a new Category III CPT code for its FemaSeed intratubal insemination procedure. This approval is expected to enhance reimbursement strategies and support broader adoption of the treatment, which has shown to significantly improve pregnancy rates compared to traditional methods. The new code will be effective from January 1, 2027.
Read more →-FEMY
Feb 4, 2026Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
Femasys Inc. has entered a strategic distribution partnership with OR Consulting to launch its product portfolio in Switzerland, including FemBloc and FemaSeed. This agreement is part of Femasys's broader European expansion strategy, which also includes recent market entries in Spain and France. The collaboration aims to enhance access to innovative women's health solutions across Europe.
Read more →-FEMY
Jan 15, 2026Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Femasys Inc. has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company must achieve this price for ten consecutive business days to maintain its listing. Femasys is committed to compliance and is monitoring its share price closely, with plans to take necessary actions if needed.
Read more →-FEMY
Jan 14, 2026Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Femasys Inc. has partnered with Refuah Health Center to enhance access to its FemaSeed product, a first-line infertility treatment. This collaboration aims to improve the availability of FemaSeed in community-based fertility care, making it more accessible and cost-effective for patients. The partnership is expected to accelerate the adoption of FemaSeed, which has demonstrated superior pregnancy rates compared to traditional methods.
Read more →Competitive Position
How FEMY ranks across every disease it competes inCompetitive Position is a premium feature
See how FEMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial